Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Conjugated estrogens oral - Teva Pharmaceutical Industries

Drug Profile

Conjugated estrogens oral - Teva Pharmaceutical Industries

Alternative Names: Cenestin; Synthetic conjugated estrogens, A

Latest Information Update: 16 Oct 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duramed Pharmaceuticals Inc
  • Class Estradiol congeners; Hormonal replacements; Osteoporosis therapies
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Atrophic vaginitis; Postmenopausal osteoporosis; Vasomotor symptoms

Most Recent Events

  • 20 Oct 2004 Data presented at the 15th Annual Meeting of the North American Menopause Society (NAMS-2004) have been added to the Women's Health therapeutic trials section
  • 06 May 2004 Cenestin® 0.45mg tablets launched for Menopausal syndrome in USA (PO)
  • 11 Feb 2004 Barr Laboratories has received approval for its sNDA for Cenestin® 0.45mg tablet for the treatment of severe vasomotor symptoms of menopause
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top